Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Idazoxan is an antagonist of α2-adrenergic receptors (α2-ARs) and imidazoline I1 and I2 receptors (IC50s = 69, 66, and 61 nM, respectively).1 It selectively binds to α2A- and α2C-ARs over α2B-ARs (Kds = 67, 69, and 407 nM, respectively), as well as α2-ARs over α1-ARs (IC50s = 0.7 and 4,000 µM, respectively).2,3 Idazoxan (0.1-5 mg/kg) increases mean arterial pressure and decreases heart rate in rabbits.3 It reverses the anti-hyperalgesic activity of 2-BFI (Item No. 42338) in rat models of inflammatory and neuropathic pain and the antidepressant-like activity of 2-BFI in the tail suspension test in mice.4,5 Idazoxan (7.5 and 10 mg/kg) reduces L-DOPA-induced dyskinesia in a cynomolgus monkey model of MPTP-induced Parkinson’s disease.6
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization of I1 and I2 imidazoline receptors in human striatum. Neurochem. Int. 30(1), 25-29 (1997).
2. The affinity and selectivity of α-
3. RX781094, a new potent α2 adrenoceptor antagonist. In vivo and in vitro studies in the rabbit. Naunyn Schmiedebergs Arch. Pharmacol. 322(3), 221-227 (1983).
4. Antihyperalgesic effects of imidazoline I2 receptor ligands in rat models of inflammatory and neuropathic pain. Br. J. Pharmacol. 171(6), 1580-1590 (2014).
5. The potential antidepressant-
6. Noradrenoceptor antagonism with idazoxan improves L-